-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with autoimmune hemolytic anemia (AIHA) are considered to be at increased risk of thrombosis and prophylactic venous thromboembolism (VTE)
The study was a retrospective study of 47 consecutive patients with
Figure 1: D-dimer levels (n=13) and Evans syndrome (n=5) in patients with warm autoimmune hemolytic anemia (WAIHA).
Figure 2: Thrombotic survival in patients with warm autoimmune hemolytic anemia (n = 47)
Table: 3 patients with
The results showed that no patients had thrombosis, and during the 15-month median observation period, 3 patients had ischemic cerebrovascular accidents
The main limitations of this study are the relatively small number of patients, the retrospective nature of the study, and the lack of tests
Original Source:
Higuchi T, Hoshi T, Toriyama M, Nakajima A, Haruki K.